Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug

Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug

Source: 
CP Wire
snippet: 

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced on 9/25/18 the initiation of PolarisDMD, the Company’s Phase 3 trial for edasalonexent in Duchenne muscular dystrophy (DMD). Edasalonexent inhibits NF-kB, which is the key link between loss of dystrophin and disease pathology and plays a fundamental role in the initiation and progression of skeletal and cardiac muscle disease in DMD.